Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762590 · ClinicalTrials.gov registry record · NA
GENetic Education Risk Assessment and TEsting Study
A NA study of Candidates for Hereditary Pancreatic Cancer Testing, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT03762590 is a NA study of Candidates for Hereditary Pancreatic Cancer Testing that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03762590, a NA study of Candidates for Hereditary Pancreatic Cancer Testing, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the GENERATE Study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients who may have genetic mutations (inherited changes). The study will measure how different methods of genetic education increase the rate of genetic testing in these families. This is an investigational study to measure the effects of two methods of genetic education. Participants may elect to undergo genetic testing as part of the study and will be asked to provide a saliva sample via a saliva-testing kit. The genetic testing done in this study is FDA approved and will be processed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Up to 1,000 participants will be enrolled in this study.
Conditions Studied
Interventions
- OTHER Doxy.me genetic education +/- Color Genomics genetic education
- OTHER Color Genomics genetic education
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03762590
The ClinicalTrials.gov registry entry for NCT03762590 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Candidates for Hereditary Pancreatic Cancer Testing appearing as the primary indexed condition, and to 2 interventions - of which Doxy.me genetic education +/- Color Genomics genetic education is the first listed.
NCT03762590 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03762590 about?
NCT03762590 is a clinical study titled "GENetic Education Risk Assessment and TEsting Study". The goal of the GENERATE Study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients who may have genetic mutations (inherited changes). The study will measure how different methods of genetic education increase the rate of genetic testing in these famil...
What is the current status of trial NCT03762590?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2019-05-08. Estimated completion is 2027-12-31.
What conditions does trial NCT03762590 study?
This clinical trial studies the following conditions: Candidates for Hereditary Pancreatic Cancer Testing.
What interventions are being tested in trial NCT03762590?
The interventions under investigation include: Doxy.me genetic education +/- Color Genomics genetic education (OTHER), Color Genomics genetic education (OTHER).
Who is sponsoring clinical trial NCT03762590?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03762590 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.